Literature DB >> 27011549

Abdominoperineal Excisions in the Treatment Regimen for Advanced and Recurrent Vulvar Cancers-Analysis of a Single-Centre Experience.

Sabine Hannes1, Johanna M Nijboer1, Alexander Reinisch1, Wolf O Bechstein1, Nils Habbe1.   

Abstract

Vulva cancer is the fourth leading gynaecological malignancy, accounting for approximately 4 % of all gynaecological cancers. Surgery represents the treatment of choice, and cases of advanced or recurrent vulvar cancers are to date a major challenge to multidisciplinary teams. Abdominoperineal excision (APE) in combination with vulvectomy and inguinal lymphadenectomy is the only curative treatment option. Patients' files of all women with squamous cell carcinoma of the vulva who underwent abdominoperineal resection were retrospectively reviewed with special regards to technical challenges the general surgeon will face. Seven women were enrolled in this retrospective study with a median age of 71 years (range 56-79 years). In six patients, the pelvic floor after abdominoperineal excision could be closed by direct suture of the levator muscles. One woman underwent abdominoperineal resection with closure of the defect using a vertical rectus abdominis myocutaneous (VRAM) flap. All women underwent radical vulvectomy, in five patients in combination with bilateral inguinal lymph node dissection. Operation time was 377 min (range 130-505 min). The median overall survival after surgery was 27 months (range 4-84 months), with a calculated 5-year survival rate of 42 %. Women with negative lymph nodes revealed a longer survival time after surgery compared to women with lymph node metastases (15.5 vs. 72 months; p = 0.09). Abdominoperineal excisions represent a powerful tool in the multidisciplinary treatment regimen of advanced or recurrent vulvar cancer. Reconstruction of the pelvic floor usually does not require myocutaneous flaps, even when facing large tumours. Despite high complication rates, radical surgery was a feasible treatment with long-term survival potential without mortality.

Entities:  

Keywords:  Abdominoperineal excision; Exenteration; Gynaecological cancer; Salvage surgery; Vulvar cancer

Year:  2015        PMID: 27011549      PMCID: PMC4775665          DOI: 10.1007/s12262-015-1273-0

Source DB:  PubMed          Journal:  Indian J Surg        ISSN: 0973-9793            Impact factor:   0.656


  20 in total

1.  In situ and invasive vulvar cancer incidence trends (1973 to 1987).

Authors:  S R Sturgeon; L A Brinton; S S Devesa; R J Kurman
Journal:  Am J Obstet Gynecol       Date:  1992-05       Impact factor: 8.661

2.  Prognostic factors in pelvic exenteration for gynecological malignancies.

Authors:  G Baiocchi; G C Guimaraes; R A Rosa Oliveira; L Y Kumagai; C C Faloppa; S Aguiar; M D Begnami; F A Soares; A Lopes
Journal:  Eur J Surg Oncol       Date:  2012-07-18       Impact factor: 4.424

3.  Pelvic exenteration in gynecologic oncology: a single institution study over 20 years.

Authors:  T Benn; R A Brooks; Q Zhang; M A Powell; P H Thaker; D G Mutch; I Zighelboim
Journal:  Gynecol Oncol       Date:  2011-03-27       Impact factor: 5.482

Review 4.  Prognostic factors in patients with carcinoma of the vulva--our own experience and literature review.

Authors:  P Blecharz; K Karolewski; T Bieda; M Klimek; J Pudelek; E Kojs; K Zur; P Dzialak; K Urbanski
Journal:  Eur J Gynaecol Oncol       Date:  2008       Impact factor: 0.196

5.  Cancer statistics, 2006.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2006 Mar-Apr       Impact factor: 508.702

Review 6.  Exenterative surgery for recurrent gynaecological malignancies.

Authors:  Christine Ang; Andrew Bryant; Desmond P J Barton; Christophe Pomel; Raj Naik
Journal:  Cochrane Database Syst Rev       Date:  2014-02-04

7.  Pelvic exenteration for primary and recurrent vulvar cancer.

Authors:  B Miller; M Morris; C Levenback; T W Burke; D M Gershenson
Journal:  Gynecol Oncol       Date:  1995-08       Impact factor: 5.482

Review 8.  Vulvar cancer surgery.

Authors:  Glauco Baiocchi; Rafael M Rocha
Journal:  Curr Opin Obstet Gynecol       Date:  2014-02       Impact factor: 1.927

9.  Role of paclitaxel and cisplatin as the neoadjuvant treatment for locally advanced squamous cell carcinoma of the vulva.

Authors:  Francesco Raspagliesi; Flavia Zanaboni; Fabio Martinelli; Santiago Scasso; Joel Laufer; Antonino Ditto
Journal:  J Gynecol Oncol       Date:  2014-01-08       Impact factor: 4.401

10.  Extralevator abdominoperineal excision (ELAPE) for rectal cancer--short-term results from the Swedish Colorectal Cancer Registry. Selective use of ELAPE warranted.

Authors:  Mattias Prytz; Eva Angenete; Jan Ekelund; Eva Haglind
Journal:  Int J Colorectal Dis       Date:  2014-06-21       Impact factor: 2.571

View more
  1 in total

1.  Electrochemotherapy as an Alternative Treatment Option to Pelvic Exenteration for Recurrent Vulvar Cancer of the Perineum Region.

Authors:  Gregor Vivod; Nina Kovacevic; Maja Čemažar; Gregor Serša; Tanja Jesenko; Maša Bošnjak; Simona Kranjc Brezar; Sebastjan Merlo
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.